Pulmatrix (PULM) had the highest return last year by a US stock in the Pharmaceuticals Industry, returning 272.8%.
| ASSET | YEAR | % RETURN |
|---|---|---|
Pulmatrix (PULM) | 2024 | 272.8% |
Eton Pharmaceuticals (ETON) | 2024 | 209.77% |
Omeros (OMER) | 2024 | 206.83% |
Trevi Therapeutics (TRVI) | 2024 | 202.94% |
Harrow Health (HROW) | 2024 | 200.63% |
Tarsus Pharmaceuticals (TARS) | 2024 | 176.85% |
Qilian International (BGM) | 2024 | 147.8% |
Wave Life Sciences (WVE) | 2024 | 147.4% |
Verona Pharma PLC ADR (VRNA) | 2024 | 141.88% |
Corcept Therapeutics (CORT) | 2024 | 127.91% |
Aclaris Therapeutics (ACRS) | 2024 | 125.45% |
CorMedix (CRMD) | 2024 | 115.43% |
Teva Pharma Industries Ltd ADR (TEVA) | 2024 | 110.51% |
Ocular Therapeutix (OCUL) | 2024 | 94.09% |
China Pharma (CPHI) | 2024 | 88.7% |
Phibro Animal Health (PAHC) | 2024 | 88.08% |
Lipocine (LPCN) | 2024 | 76.81% |
Aquestive Therapeutics (AQST) | 2024 | 76.24% |
Mediwound (MDWD) | 2024 | 71.98% |
Nektar Therapeutics (NKTR) | 2024 | 64.86% |
Enliven Therapeutics (ELVN) | 2024 | 62.1% |
Xeris Pharmaceuticals (XERS) | 2024 | 46.75% |
Milestone Pharmaceuticals (MIST) | 2024 | 43.9% |
Eli Lilly and (LLY) | 2024 | 33.88% |
Cumberland Pharmaceuticals (CPIX) | 2024 | 33.15% |
